Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tepilamide fumarate
- Development stage
- Phase 2
- Lead developer
- Dr. Reddy's Laboratories
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Tepilamide fumarate (PPC-06, XP23829) is an oral, extended-release small molecule prodrug of monomethyl fumarate (MMF), belonging to the fumaric acid ester (FAE) class. Originally developed by XenoPort and subsequently licensed to Dr. Reddy's Laboratories, the drug is designed to be absorbed throughout the gastrointestinal tract and rapidly hydrolyzed to release MMF, the active moiety. MMF acts as an immunomodulator and neuroprotective agent, primarily through the activation of the Nrf2 (nuclear factor erythroid 2-related factor 2) antioxidant pathway and agonism of the HCAR2 (hydroxycarboxylic acid receptor 2) receptor. Tepilamide fumarate has been investigated for the treatment of moderate-to-severe plaque psoriasis, relapsing forms of multiple sclerosis, and Parkinson's disease. In clinical trials for psoriasis, it demonstrated efficacy in improving PASI and IGA scores with a safety profile characterized by gastrointestinal side effects and lymphopenia, aiming for improved tolerability compared to traditional dimethyl fumarate formulations.
- Other names
- tepilamide fumaratePPC-06PPC06PPC 06XP23829XP-23829XP 23829
02
Targets
NF-κB
Beyond the preview
Go deeper on tepilamide fumarate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tepilamide fumarate.